Investigating Utility of ctDNA and Tumour Evolution in Advanced Thyroid Cancer

Although most thyroid cancers are treated and cured successfully there are still 30% who recur after many years. This will eventually progress and at this point may become incurable with treatment options including complex and high risk surgery. The overall efficacy of systemic treatment in advanced thyroid cancer has a good initial response in most patients but not all. The study will collect tissues and blood samples for various protein analysis, nucleic acid extraction and live cell analysis in order to try and detect the presence of plasma ctDNA at baseline of eligible patients.

NCT Number	NCT05837260
Lead Sponsor	Royal Marsden NHS Foundation Trust
Conditions	Thyroid Cancer
Enrollment	120 participants
Start Date	2023-03-23
Primary Completion	2027-02-07 (estimated)
Study Completion	2027-02-07 (estimated)
Updated on ClinicalTrials.gov	2024-08-09